Zeitschriftenaufsatz
|
2017
RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer
Autor:in
Rao, Shuan; Sigl, Verena; Wimmer, Reiner A.; Novatchkova, M.; Jais, Alexander; Wagner, Gabriel; Handschuh, Stephan; Uribesalgo, Iris; Hagelkruys, Astrid; Kozieradzki, Ivona; Tortola, Luigi; Nitsch, Roberto; Cronin, Shane; Orthofer, Michael; Branstetter, Daniel G.; Canon, Jude R.; Rossi, John; D'Arcangelo, Manolo; Botling, Johan; Micke, Patrick; La Fleur, Linnea; Edlund, Karolina; Bergqvist, Michael; Ekman, Simon; Lendl, Thomas; Popper, Helmut; Takayanagi, Hiroshi; Kenner, Lukas; Hirsch, Fred R.; Dougall, William C.; Penninger, Josef
Publikationen als Autor:in / Herausgeber:in der Vetmeduni
Journal
Abstrakt
Lung cancer is the leading cause of cancer deaths. Besides smoking, epidemiological studies have linked female sex hormones to lung cancer in women; however, the underlying mechanisms remain unclear. Here we report that the receptor activator of nuclear factor-kB (RANK), the key regulator of osteoclastogenesis, is frequently expressed in primary lung tumors, an active RANK pathway correlates with decreased survival, and pharmacologic RANK inhibition reduces tumor growth in patient-derived lung cancer xenografts. Clonal genetic inactivation of KRas(G12D) in mouse lung epithelial cells markedly impairs the progression of KRas(G12D)-driven lung cancer, resulting in a significant survival advantage. Mechanistically, RANK rewires energy homeostasis in human and murine lung cancer cells and promotes expansion of lung cancer stem-like cells, which is blocked by inhibiting mitochondrial respiration. Our data also indicate survival differences in KRas(G12D)-driven lung cancer between male and female mice, and we show that female sex hormones can promote lung cancer progression via the RANK pathway. These data uncover a direct role for RANK in lung cancer and may explain why female sex hormones accelerate lung cancer development. Inhibition of RANK using the approved drug denosumab may be a therapeutic drug candidate for primary lung cancer.
Schlagwörter
RANK; energy homeostasis; lung cancer; lung cancer stem-like cells
Dokumententyp
Originalarbeit
CC Lizenz
CCBY
Open Access Type
Hybrid
ISSN/eISSN
0890-9369 - 1549-5477
WoS ID
PubMed ID